title: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis.
abstract: The formation and guidance of specialized endothelial tip cells is essential for both developmental and pathological angiogenesis. Notch-1 signalling regulates the generation of tip cells, which respond to gradients of vascular endothelial growth factor (VEGF-A). The molecular cues and signalling pathways that control the guidance of tip cells are poorly understood. Bidirectional signalling by Eph receptors and ephrin ligands represents one of the most important guidance cues involved in axon path finding. Here we show that ephrin-B2 reverse signalling involving PDZ interactions regulates endothelial tip cell guidance to control angiogenic sprouting and branching in physiological and pathological angiogenesis. In vivo, ephrin-B2 PDZ-signalling-deficient mice (ephrin-B2DeltaV) exhibit a reduced number of tip cells with fewer filopodial extensions at the vascular front in the mouse retina. In pathological settings, impaired PDZ signalling decreases tumour vascularization and growth. Mechanistically, we show that ephrin-B2 controls VEGF receptor (VEGFR)-2 internalization and signalling. Importantly, internalization of VEGFR2 is necessary for activation and downstream signalling of the receptor and is required for VEGF-induced tip cell filopodial extension. Together, our results suggest that ephrin-B2 at the tip cell filopodia regulates the proper spatial activation of VEGFR2 endocytosis and signalling to direct filopodial extension. Blocking ephrin-B2 reverse signalling may be an attractive alternative or combinatorial anti-angiogenic therapy strategy to disrupt VEGFR2 function in tumour angiogenesis.
authors.affiliation: Frankfurt Institute for Molecular Life Sciences and Institute of Cell Biology and Neuroscience, Goethe University Frankfurt, Max-von-Laue-Strasse 9, D-60438 Frankfurt am Main, Germany.
authors.forename: Suphansa
authors.initials: S
authors.lastname: Sawamiphak
authors.forename: Sascha
authors.initials: S
authors.lastname: Seidel
authors.forename: Clara L
authors.initials: CL
authors.lastname: Essmann
authors.forename: George A
authors.initials: GA
authors.lastname: Wilkinson
authors.forename: Mara E
authors.initials: ME
authors.lastname: Pitulescu
authors.forename: Till
authors.initials: T
authors.lastname: Acker
authors.forename: Amparo
authors.initials: A
authors.lastname: Acker-Palmer
mesh_terms: D000818:Animals; D001254:Astrocytoma / Q000098:blood supply* / Q000378:metabolism* / Q000473:pathology; D001921:Brain / Q000098:blood supply; D002478:Cells, Cultured; D004705:Endocytosis; D042783:Endothelial Cells / Q000166:cytology / Q000378:metabolism; D036388:Ephrin-B2 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D018919:Neovascularization, Physiologic; D011554:Pseudopodia / Q000378:metabolism; D012160:Retina; D012171:Retinal Vessels / Q000166:cytology / Q000502:physiology; D015398:Signal Transduction; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism*
chemical_list: D036388:Ephrin-B2; D040301:Vascular Endothelial Growth Factor Receptor-2
references.citation: Cell. 2001 Jan 12;104(1):57-69
references.pmid: 11163240
references.citation: Mol Cell. 2002 Apr;9(4):725-37
references.pmid: 11983165
references.citation: Dev Cell. 2006 Jun;10(6):839-50
references.pmid: 16740485
references.citation: J Cell Biol. 2003 Jun 23;161(6):1163-77
references.pmid: 12810700
references.citation: J Cell Biol. 2006 Aug 14;174(4):593-604
references.pmid: 16893970
references.citation: FASEB J. 2009 May;23(5):1490-502
references.pmid: 19136612
references.citation: Nature. 2004 Nov 11;432(7014):179-86
references.pmid: 15510105
references.citation: Prog Retin Eye Res. 2006 May;25(3):277-95
references.pmid: 16515881
references.citation: Circ Res. 2009 Feb 27;104(4):428-41
references.pmid: 19246687
references.citation: Nature. 2005 Dec 15;438(7070):932-6
references.pmid: 16355210
references.citation: Nature. 2010 May 27;465(7297):483-6
references.pmid: 20445537
references.citation: Dev Cell. 2008 Aug;15(2):178-9
references.pmid: 18694556
references.citation: Cancer Cell. 2003 Aug;4(2):133-46
references.pmid: 12957288
references.citation: FASEB J. 2005 Oct;19(12):1692-4
references.pmid: 16049137
references.citation: Cell. 2007 Aug 24;130(4):691-703
references.pmid: 17719546
references.citation: Nat Neurosci. 2008 Sep;11(9):1035-43
references.pmid: 19160501
references.citation: Nat Cell Biol. 2003 Oct;5(10):869-78
references.pmid: 12973358
references.citation: Genes Dev. 2005 Feb 1;19(3):397-410
references.pmid: 15687262
references.citation: Nat Neurosci. 2004 Jan;7(1):33-40
references.pmid: 14699416
references.citation: Invest Ophthalmol Vis Sci. 1996 Nov;37(12):2367-75
references.pmid: 8933753
references.citation: J Neurosci. 2006 Nov 8;26(45):11575-81
references.pmid: 17093078
references.citation: Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3500-10
references.pmid: 12407162
references.citation: Genes Dev. 1999 Feb 1;13(3):295-306
references.pmid: 9990854
references.citation: Nature. 2008 Jul 31;454(7204):656-60
references.pmid: 18594512
references.citation: Dev Cell. 2005 Aug;9(2):197-207
references.pmid: 16054027
references.citation: Dev Dyn. 2008 Aug;237(8):2220-34
references.pmid: 18651661
references.citation: Trends Cell Biol. 2007 May;17(5):230-8
references.pmid: 17420126
references.citation: Nature. 1999 Jul 1;400(6739):77-81
references.pmid: 10403252
references.citation: Dev Cell. 2009 Feb;16(2):196-208
references.pmid: 19217422
references.citation: Nature. 2005 Dec 15;438(7070):960-6
references.pmid: 16355161
references.citation: Nature. 1988 Apr 28;332(6167):834-7
references.pmid: 3282180
references.citation: Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78
references.pmid: 17522591
references.citation: Cell. 2008 Apr 4;133(1):38-52
references.pmid: 18394988